The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy

Future Medicinal Chemistry

Volumn 6, Issue 2, 2014, Pages 205-222

  Ooi, Jenny Y Y ^a   Bernardo, Bianca C ^a   McMullen, Julie R ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 103; MICRORNA 122; MICRORNA 124; MICRORNA 126; MICRORNA 130A; MICRORNA 133A; MICRORNA 133B; MICRORNA 143; MICRORNA 144; MICRORNA 145; MICRORNA 146A; MICRORNA 15; MICRORNA 15A; MICRORNA 15B; MICRORNA 16; MICRORNA 195; MICRORNA 199B; MICRORNA 208A; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 29; MICRORNA 34; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 378; MICRORNA 497; UNCLASSIFIED DRUG;

CLINICAL FEATURE; GENE EXPRESSION; GENE TARGETING; GENETIC MODEL; HEART; HEART DEVELOPMENT; HEART MUSCLE CELL; HEART SIZE; HEART VENTRICLE HYPERTROPHY; HUMAN; MOUSE MODEL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; FEMALE; HEART; HEPATITIS C; MICRORNAS; PHYSICAL CONDITIONING, ANIMAL; PREGNANCY; SIGNAL TRANSDUCTION;

EID: 84893197806     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.196     Document Type: Review

References (93)

1. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol. Ther. 128(1), 191-227 (2010
2. Bernardo BC, Charchar FJ, Lin RC, McMullen JR. A microRNA guide for clinicians and basic scientists: Background and experimental techniques. Heart Lung Circ. 21(3), 131-142 (2012
3. Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J. Mol. Cell. Cardiol. 28(8), 1737-1746 (1996
4. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am. J. Physiol. 271(5 Pt 2), H2183-H2189 (1996
5. Walsh S, Ponten A, Fleischmann BK, Jovinge S. Cardiomyocyte cell cycle control and growth estimation in vivo - Analysis based on cardiomyocyte nuclei. Cardiovasc. Res. 86(3), 365-373 (2010
6. Weeks KL, McMullen JR. The athletés heart vs. the failing heart: Can signaling explain the two distinct outcomes? Physiology (Bethesda) 26(2), 97-105 (2011
7. Shioi T, Kang PM, Douglas PS et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19(11), 2537-2548 (2000
8. McMullen JR, Shioi T, Zhang L et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100(21), 12355-12360 (2003
9. Weeks KL, Gao X, Du XJ et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5(4), 523-534 (2012
10. DeBosch B, Treskov I, Lupu TS et al. Akt1 is required for physiological cardiac growth. Circulation 113(17), 2097-2104 (2006
11. Chung E, Yeung F, Leinwand LA. Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation. J. Appl. Physiol. 112(9), 1564-1575 (2012
12. Chung E, Yeung F, Leinwand LA. Calcineurin activity is required for cardiac remodelling in pregnancy. Cardiovasc. Res. 100(3), 402-410 (2013
13. Gonzalez AM, Osorio JC, Manlhiot C, Gruber D, Homma S, Mital S. Hypertrophy signaling during peripartum cardiac remodeling. Am. J. Physiol. Heart Circ. Physiol. 293(5), H3008-H3013 (2007
14. Hilfiker-Kleiner D, Kaminski K, Podewski E et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128(3), 589-600 (2007
15. Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am. J. Physiol. Heart Circ. Physiol. 300(3), H931-H942 (2011
16. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004
17. Papoutsidakis N, Deftereos S, Kaoukis A et al. MicroRNAs and the heart: Small things do matter. Curr. Top. Med .Chem. 13(2), 216-230 (2013
18. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993
19. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75(5), 855-862 (1993
20. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol. Rev. 91(3), 827-887 (2011
21. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1), 15-20 (2005
22. Chen JF, Murchison EP, Tang R et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl Acad. Sci. USA 105(6), 2111-2116 (2008
23. da Costa Martins PA, Bourajjaj M, Gladka M et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118(15), 1567-1576 (2008
24. Da Costa Martins PA, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc. Res. 93(4), 563-572 (2012
25. Orenes-Pinero E, Montoro-Garcia S, Patel JV, Valdes M, Marin F, Lip GY. Role of microRNAs in cardiac remodelling: New insights and future perspectives. Int. J. Cardiol. 167(5), 1651-1659 (2012
26. Thum T, Galuppo P, Wolf C et al. MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116(3), 258-267 (2007
27. McMullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104(2), 612-617 (2007
28. Jankowski M, Wang D, Mukaddam-Daher S, Gutkowska J. Pregnancy alters nitric oxide synthase and natriuretic peptide systems in the rat left ventricle. J. Endocrinol. 184(1), 209-217 (2005
29. Care A, Catalucci D, Felicetti F et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13(5), 613-618 (2007
30. Soci UP, Fernandes T, Hashimoto NY et al. MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. Physiol. Genomics 43(11), 665-673 (2011
31. van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13027-13032 (2008
32. Fernandes T, Hashimoto NY, Magalhaes FC et al. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory microRNAs, decreased angiotensin-converting enzyme-Angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-Angiotensin (1-7). Hypertension 58(2), 182-189 (2011
33. Grobe JL, Mecca AP, Lingis M et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am. J. Physiol. Heart Circ. Physiol. 292(2), H736-H742 (2007
34. Raizada MK, Ferreira AJ. ACE2: A new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 50(2), 112-119 (2007
35. Mercure C, Yogi A, Callera GE et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res. 103(11), 1319-1326 (2008
36. Goyal R, Goyal D, Leitzke A, Gheorghe CP, Longo LD. Brain renin-Angiotensin system: Fetal epigenetic programming by maternal protein restriction during pregnancy. Reprod. Sci. 17(3), 227-238 (2010
37. Boettger T, Beetz N, Kostin S et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 119(9), 2634-2647 (2009
38. Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI, DE Oliveira EM. Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Med. Sci. Sports Exerc. 44(8), 1453-1462 (2012
39. Kuhnert F, Mancuso MR, Hampton J et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 135(24), 3989-3993 (2008
40. Wang S, Aurora AB, Johnson BA et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15(2), 261-271 (2008
41. Ma Z, Qi J, Meng S, Wen B, Zhang J. Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway. Eur. J. Appl. Physiol. 113(10), 2473-2486 (2013
42. Lin RC, Weeks KL, Gao XM et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: Identification of PI3K-regulated miRNA and mRNA. Arterioscler. Thromb. Vasc. Biol. 30(4), 724-732 (2010
43. Bernardo BC, Gao XM, Winbanks CE et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl Acad. Sci. USA 109(43), 17615-17620 (2012
44. Condorelli G, Drusco A, Stassi G et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl Acad. Sci. USA 99(19), 12333-12338 (2002
45. Porrello ER, Johnson BA, Aurora AB et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ. Res. 109(6), 670-679 (2011
46. Chen J, Huang ZP, Seok HY et al. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ. Res. 112(12), 1557-1566 (2013
47. Knezevic I, Patel A, Sundaresan NR et al. A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: Implications in postnatal cardiac remodeling and cell survival. J. Biol.Chem. 287(16), 12913-12926 (2012
48. Ganesan J, Ramanujam D, Sassi Y et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-Activated protein kinase pathway factors. Circulation 127(21), 2097-2106 (2013
49. Halkein J, Tabruyn SP, Ricke-Hoch M et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 123(5), 2143-2154 (2013
50. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nat. Rev. Drug Discov. 11(11), 860-872 (2012
51. Elmen J, Lindow M, Silahtaroglu A et al. Antagonism of microRNA-122 in mice by systemically administered LNA-AntimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36(4), 1153-1162 (2008
52. Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 452(7189), 896-899 (2008
53. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685-1694 (2013
54. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 3(1), 1 (2012
55. Krutzfeldt J, Kuwajima S, Braich R et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 35(9), 2885-2892 (2007
56. Obad S, dos Santos CO, Petri A et al. Silencing of microRNA families by seed-Targeting tiny LNAs. Nat. Genet. 43(4), 371-378 (2011
57. Esau C, Davis S, Murray SF et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3(2), 87-98 (2006
58. Boon RA, Iekushi K, Lechner S et al. MicroRNA-34a regulates cardiac ageing and function. Nature 495(7439), 107-110 (2013
59. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224), 980-984 (2008
60. Rayner KJ, Esau CC, Hussain FN et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478(7369), 404-407 (2011
61. Montgomery RL, Hullinger TG, Semus HM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure/clinical perspective. Circulation 124(14), 1537-1547 (2011
62. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962), 198-201 (2010
63. Porrello ER, Mahmoud AI, Simpson E et al. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc. Natl Acad. Sci. USA 110(1), 187-192 (2013
64. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438(7068), 685-689 (2005
65. Patrick DM, Montgomery RL, Qi X et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120(11), 3912-3916 (2010
66. Hullinger TG, Montgomery RL, Seto AG et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110(1), 71-81 (2012
67. Editors T. Circulation research thematic synopsis: MicroRNAs. Circ. Res. 113(4), e30-e41 (2013
68. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ. Res. 103(9), 919-928 (2008
69. Latronico MVG, Condorelli G: MicroRNAs and cardiac pathology. Nat. Rev. Cardiol. 6(6), 418-429 (2009
70. Greco S, Fasanaro P, Castelvecchio S et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61(6), 1633-1641 (2012
71. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316(5824), 575-579 (2007
72. Callis TE, Pandya K, Seok HY et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119(9), 2772-2786 (2009
73. White E. Mechanical modulation of cardiac microtubules. Pflugers Arch. 462(1), 177-184 (2011
74. da Costa Martins PA, Salic K, Gladka MM et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-Amplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 12(12), 1220-1227 (2010
75. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ. Res. 110(3), 496-507 (2012
76. Ebert MS, Sharp PA. MicroRNA sponges: Progress and possibilities. RNA 16(11), 2043-2050 (2010
77. Zhu H, Fan GC. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am. J. Cardiovasc. Dis. 1(2), 138-149 (2011
78. Gidlof O, Smith JG, Miyazu K et al. Circulating cardio-enriched microRNAs are associated with long-Term prognosis following myocardial infarction. BMC Cardiovasc. Disord. 13, 12 (2013
79. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem. 55(11), 1944-1949 (2009
80. Matsumoto S, Sakata Y, Nakatani D et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ. Res. 13(3), 322-326 (2013
81. Baggish AL, Hale A, Weiner RB et al. Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J. Physiol. 589(Pt 16), 3983-3994 (2011
82. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121(8), 1022-1032 (2010
83. Wang X, Zhu H, Zhang X et al. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc. Res. 94(2), 379-390 (2012
84. Zhang X, Wang X, Zhu H et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J. Mol. Cell. Cardiol. 49(5), 841-850 (2010
85. Li R, Yan G, Li Q et al. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H(2)O(2))-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS ONE 7(9), e44907 (2012
86. Wang C, Wang S, Zhao P et al. MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. J. Cell Biochem. 113(6), 2040-2046 (2012
87. Kumarswamy R, Lyon AR, Volkmann I et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur. Heart J. 33(9), 1067-1075 (2012
88. Elia L, Contu R, Quintavalle M et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120(23), 2377-2385 (2009
89. Duisters RF, Tijsen AJ, Schroen B et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104(2), 170-178, 176p following 178 (2009
90. Roy S, Khanna S, Hussain SR et al. MicroRNA expression in response to murine myocardial infarction: MiR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 82(1), 21-29 (2009
91. Hu S, Huang M, Li Z et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122(11 Suppl.), S124-S131 (2010
92. Wang J, Song Y, Zhang Y et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell. Res. 22(3), 516-527 (2012
93. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 87(3), 535-544 (2010